Alliance for Cancer Gene Therapy welcomes two new members to its Board of Directors, further expanding its powerful network of accomplished innovators in science, business, finance and advocacy.
Credit: Gbola Amusa, MD, Chardan.
Alliance for Cancer Gene Therapy welcomes two new members to its Board of Directors, further expanding its powerful network of accomplished innovators in science, business, finance and advocacy.
Gbola Amusa, MD, MBA, CFA, partner and chief scientific officer of Chardan, is responsible for advising disruptive health care companies on capital formation strategies, mergers and acquisitions, and other transactions. Dr. Amusa joined Chardan at the end of 2014 to focus on identifying companies that will generate exceptionally high long-term investment returns from creating and sharing in real value for society. While in the Chardan Equity Research Department from 2014 through July 2021, Dr. Amusa’s coverage, top picks and counter-consensus calls were all associated with exceptional alpha generation. In a 2019 study by TipRanks, Dr. Amusa was ranked second out of more than 6,000 Wall Street analysts for his stock-picking performance.
Chen Schor, MBA, CPA, is president and chief executive officer of Adicet Bio, a leader in the field of gamma-delta CAR T-cell therapies for the treatment of cancer. With more than 25 years of global biopharmaceutical leadership experience, he has led several biotech companies across all stages, from formation to early-stage discovery and to publicly traded multi-product companies with significant industry partnerships. Mr. Schor is chairman of the Board of Directors for Carbon Biosciences, a gene therapy company; and a member of the Board of Directors for Karyopharm Therapeutics, a commercial stage oncology company.
“These stellar additions to the ACGT Board of Directors team reflect our growing alliance of world class scientists, biotech and pharma leaders, venture capitalists, philanthropists and patient advocates,” says Kevin Honeycutt, ACGT chief executive officer and president. “Their vision, experience and commitment are helping ACGT achieve life-changing breakthroughs in cancer cell and gene therapies.”
Members of the Alliance for Cancer Gene Therapy Board of Directors provide sound governance, advocacy and stewardship to advance the organization’s mission and ensure its sustainability. The integrated perspectives of its influential innovators reflect the breadth of the organization’s stakeholders – from world class scientists, biotech and pharma leaders to venture capitalists, philanthropists and patient advocates.
For more information, visit acgtfoundation.org or join the Alliance for Cancer Gene Therapy community on Facebook, Twitter, LinkedIn, Instagram and YouTube.
Alliance for Cancer Gene Therapy
For 20 years, Alliance for Cancer Gene Therapy has funded research that is bringing innovative treatment options to people living with deadly cancers – treatments that save lives and offer new hope to all cancer patients. Alliance for Cancer Gene Therapy funds researchers who are pioneering the potential of cancer cell and gene therapy – talented visionaries whose scientific advancements are driving the development of groundbreaking treatments for ovarian, prostate, sarcoma, glioblastoma, melanoma and pancreatic cancers. 100% of all public funds raised by Alliance for Cancer Gene Therapy directly support research and programs. For more information, visit acgtfoundation.org, call (203) 358-5055, or join the Alliance for Cancer Gene Therapy community on Facebook, Twitter, LinkedIn, Instagram and YouTube.
